Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Roth Capital Impressed by Speed of Ligand (LGND) Capitalizing on OMT Acquisition; Affirms at 'Buy'
January 13, 2016 11:56 AM ESTRoth Capital reaffirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $146 price target after Ligand announced entering into a worldwide license agreement with Emergent BioSolutions Inc. (NYSE:... More
